Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04716153 | Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients…(RE-NEZ-SENS) | N/A | terminated | Jan 20, 2021 | University Hospital, Montpellier | Enrolement difficulties | Enrollment / accrual |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | Phase 2 | terminated | Dec 29, 2021 | Novartis Pharmaceuticals | The study was terminated since the sponsor made the decision to discontinue further development of… | Other (stated, no rule matched) |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With… | Phase 1 / Phase 2 | withdrawn | Jul 17, 2025 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT05675319 | Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for…(AlloRelapseMM) | Phase 3 | terminated | Jan 9, 2023 | Universitätsklinikum Hamburg-Eppendorf | The reason for the end of recruitment is that the recruitment target could not be achieved despite… | Enrollment / accrual |
| NCT04123418 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | Phase 1 | terminated | Oct 10, 2019 | Novartis Pharmaceuticals | The decision was made for business reasons and was not based on any safety or tolerability concerns | Safety / toxicity |
| NCT03758417 | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy…(CARTIFAN-1) | Phase 2 | terminated | Nov 29, 2018 | Nanjing Legend Biotech Co. | The study was terminated early due to a strategic realignment of the sponsor's business plan, not… | Safety / toxicity |
| NCT01794572 | Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st…(TOMMY) | N/A | terminated | Feb 20, 2013 | Institut Cancerologie de l'Ouest | Low patient recruitement rate and modification of the therapeutic standard | Enrollment / accrual |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired…(DREAMM 13) | Phase 1 | withdrawn | May 21, 2020 | GlaxoSmithKline | Sponsor Decision | Sponsor / business decision |
| NCT06304636 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma(DC15-MM-01) | Phase 1 | terminated | Mar 12, 2024 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated | Enrollment / accrual |
| NCT05065047 | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell… | Phase 1 | terminated | Oct 1, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | Incyte Corporation | This decision follows recruitment difficulties. No safety-related concerns impacted this decision. | Safety / toxicity |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic…(LIMBER) | Phase 1 / Phase 2 | terminated | Oct 9, 2020 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in… | Phase 2 | terminated | Jul 18, 2018 | University of California, San Diego | The trial met its primary endpoint. | Other (stated, no rule matched) |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | Phase 1 | withdrawn | Dec 11, 2014 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn by PI | Other (stated, no rule matched) |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological… | Phase 1 | terminated | Jan 8, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT03287908 | A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or… | Phase 1 | terminated | Sep 19, 2017 | Amgen | business decision, not safety reasons. | Safety / toxicity |
| NCT04405167 | Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | Phase 1 | terminated | May 28, 2020 | University of Pennsylvania | Slow accrual at the time when sufficient participants were already enrolled to answer the… | Enrollment / accrual |
| NCT04300335 | The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma | N/A | suspended | Mar 9, 2020 | Medical University of Vienna | The study was not started because the necessary resources could not yet be secured after COVID-19,… | COVID-19 / pandemic |
| NCT04111809 | Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With…(AMBROBiMM) | — | terminated | Oct 1, 2019 | Assistance Publique - Hôpitaux de Paris | Inability to conduct the study | Other (stated, no rule matched) |
| NCT03376477 | Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in… | Phase 2 | terminated | Dec 18, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | loss of funding | Funding |
| NCT03015792 | Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 1 | terminated | Jan 10, 2017 | Mayo Clinic | Drug company decided to not fund the phase 2 portion | Funding |
| NCT05655546 | ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised… | N/A | terminated | Dec 19, 2022 | Scripps Translational Science Institute | On May 13, 2024, the FDA released a communication that Cue Health tests should no longer be used. | Other (stated, no rule matched) |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | Phase 2 | terminated | Mar 5, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT06588660 | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Sep 19, 2024 | University of Washington | Study terminated due to end of funding. | Funding |
| NCT04493411 | Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using… | N/A | terminated | Jul 30, 2020 | University of Texas Southwestern Medical Center | Funding expired before enrollment goal could be reached. | Enrollment / accrual |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT05442580 | CART-38 in Adult AML and MM Patients | Phase 1 | terminated | Jul 5, 2022 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05121103 | A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative… | Phase 1 | terminated | Nov 16, 2021 | Epizyme, Inc. | Strategic business decision | Sponsor / business decision |
| NCT05027594 | Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Aug 30, 2021 | Nerviano Medical Sciences | The decision is not based on emerging safety or efficacy concerns but on strategic reasons related… | Safety / toxicity |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | Phase 1 / Phase 2 | terminated | May 9, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Poor accrual | Enrollment / accrual |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | Phase 2 | withdrawn | May 18, 2010 | Situs Cancer Research Center | Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche… | Drug supply |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed,… | Phase 1 | terminated | May 19, 2021 | Mayo Clinic | Low/slow accrual - did not proceed to Phase 2 | Enrollment / accrual |
| NCT04570631 | Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in… | Phase 1 | terminated | Sep 30, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Jun 21, 2019 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated. | Enrollment / accrual |
| NCT05833737 | Corneal Findings in Patients Treated With Belantamab Mafodotin | — | terminated | Apr 27, 2023 | Medical University of Vienna | Study medication market withdrawal by FDA. | Other (stated, no rule matched) |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT04892446 | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | May 19, 2021 | Gilead Sciences | This study was terminated early due to the Sponsor's decision to discontinue development of the… | Sponsor / business decision |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed… | Phase 1 | terminated | Apr 3, 2018 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple… | Phase 1 / Phase 2 | terminated | May 21, 2021 | University of Maryland, Baltimore | The study was terminated due to FDA withdrawal of the drug and lack of enrollment with available… | Enrollment / accrual |
| NCT03871829 | Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously… | Phase 2 | terminated | Mar 12, 2019 | Janssen Research & Development, LLC | The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee… | Efficacy / futility |
| NCT04975399 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed… | Phase 1 | terminated | Jul 23, 2021 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT01997840 | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in… | Phase 1 / Phase 2 | terminated | Nov 28, 2013 | Celgene | Change in business priorities. | Sponsor / business decision |
| NCT03457142 | Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma… | Phase 2 | terminated | Mar 7, 2018 | Roswell Park Cancer Institute | funding ended | Funding |
| NCT02291965 | Blood Samples to Identify Biomarkers of Busulfan | — | terminated | Nov 17, 2014 | Fred Hutchinson Cancer Center | Study terminated due to end of funding | Funding |
| NCT06352866 | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | Phase 2 | withdrawn | Apr 8, 2024 | Jack Khouri, MD | Funding unavailable | Funding |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With… | Phase 1 / Phase 2 | terminated | Oct 23, 2024 | GlaxoSmithKline | The study was terminated due to lack of efficacy | Efficacy / futility |
| NCT04700176 | A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in… | Phase 2 | terminated | Jan 7, 2021 | Hackensack Meridian Health | Low Accrual | Enrollment / accrual |
| NCT02761187 | An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple… | — | terminated | May 4, 2016 | Takeda | This study was stopped 3 years early due to business reprioritization within Takeda | Sponsor / business decision |
| NCT03683277 | IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic(IFM2014-01) | Phase 2 | terminated | Sep 25, 2018 | Intergroupe Francophone du Myelome | Recruitment issue, 26 patients enrolled instead of 70 initially planned | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jan 20, 2026source: clinicaltrials